PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy

Tricia R. Cottrell, Janis M Taube

Research output: Contribution to journalReview article

Abstract

PD-L1 checkpoint blockade is revolutionizing cancer therapy, and biomarkers capable of predicting which patients are most likely to respond are highly desired. The detection of PD-L1 protein expression by immunohistochemistry can enrich for response to anti-PD-(L)1 blockade in a variety of tumor types, but is not absolute. Limitations of current commercial PD-L1 immunohistochemical (IHC) assays and improvements anticipated in next-generation PD-L1 testing are reviewed. Assessment of tumor-infiltrating lymphocytes in conjunction with PD-L1 testing could improve specificity by distinguishing adaptive (interferon γ driven and cytotoxic T-lymphocyte associated) from constitutive (non-immune mediated) expression. The presence of a high tumor mutational burden also enriches for response to therapy, and early data indicate that this may provide additive predictive value beyond PD-L1 IHC alone. As candidate biomarkers continue to emerge, the pathologist's assessment of the tumor microenvironment on hematoxylin-eosin stain combined with PD-L1 IHC remains a rapid and robust way to evaluate the tumor-immune dynamic.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalCancer Journal (United States)
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Biomarkers
Tumor-Infiltrating Lymphocytes
Tumor Microenvironment
Cytotoxic T-Lymphocytes
Hematoxylin
Eosine Yellowish-(YS)
Tumor Biomarkers
Tumor Burden
Interferons
Neoplasms
Coloring Agents
Immunohistochemistry
Therapeutics
Proteins
Pathologists

Keywords

  • PD-(L)1
  • PD-(L)1 checkpoint blockade
  • PD-L1 testing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy. / Cottrell, Tricia R.; Taube, Janis M.

In: Cancer Journal (United States), Vol. 24, No. 1, 01.01.2018, p. 41-46.

Research output: Contribution to journalReview article

@article{cef43ac951db4b56a04f827c444181f8,
title = "PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy",
abstract = "PD-L1 checkpoint blockade is revolutionizing cancer therapy, and biomarkers capable of predicting which patients are most likely to respond are highly desired. The detection of PD-L1 protein expression by immunohistochemistry can enrich for response to anti-PD-(L)1 blockade in a variety of tumor types, but is not absolute. Limitations of current commercial PD-L1 immunohistochemical (IHC) assays and improvements anticipated in next-generation PD-L1 testing are reviewed. Assessment of tumor-infiltrating lymphocytes in conjunction with PD-L1 testing could improve specificity by distinguishing adaptive (interferon γ driven and cytotoxic T-lymphocyte associated) from constitutive (non-immune mediated) expression. The presence of a high tumor mutational burden also enriches for response to therapy, and early data indicate that this may provide additive predictive value beyond PD-L1 IHC alone. As candidate biomarkers continue to emerge, the pathologist's assessment of the tumor microenvironment on hematoxylin-eosin stain combined with PD-L1 IHC remains a rapid and robust way to evaluate the tumor-immune dynamic.",
keywords = "PD-(L)1, PD-(L)1 checkpoint blockade, PD-L1 testing",
author = "Cottrell, {Tricia R.} and Taube, {Janis M}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/PPO.0000000000000301",
language = "English (US)",
volume = "24",
pages = "41--46",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "1",

}

TY - JOUR

T1 - PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy

AU - Cottrell, Tricia R.

AU - Taube, Janis M

PY - 2018/1/1

Y1 - 2018/1/1

N2 - PD-L1 checkpoint blockade is revolutionizing cancer therapy, and biomarkers capable of predicting which patients are most likely to respond are highly desired. The detection of PD-L1 protein expression by immunohistochemistry can enrich for response to anti-PD-(L)1 blockade in a variety of tumor types, but is not absolute. Limitations of current commercial PD-L1 immunohistochemical (IHC) assays and improvements anticipated in next-generation PD-L1 testing are reviewed. Assessment of tumor-infiltrating lymphocytes in conjunction with PD-L1 testing could improve specificity by distinguishing adaptive (interferon γ driven and cytotoxic T-lymphocyte associated) from constitutive (non-immune mediated) expression. The presence of a high tumor mutational burden also enriches for response to therapy, and early data indicate that this may provide additive predictive value beyond PD-L1 IHC alone. As candidate biomarkers continue to emerge, the pathologist's assessment of the tumor microenvironment on hematoxylin-eosin stain combined with PD-L1 IHC remains a rapid and robust way to evaluate the tumor-immune dynamic.

AB - PD-L1 checkpoint blockade is revolutionizing cancer therapy, and biomarkers capable of predicting which patients are most likely to respond are highly desired. The detection of PD-L1 protein expression by immunohistochemistry can enrich for response to anti-PD-(L)1 blockade in a variety of tumor types, but is not absolute. Limitations of current commercial PD-L1 immunohistochemical (IHC) assays and improvements anticipated in next-generation PD-L1 testing are reviewed. Assessment of tumor-infiltrating lymphocytes in conjunction with PD-L1 testing could improve specificity by distinguishing adaptive (interferon γ driven and cytotoxic T-lymphocyte associated) from constitutive (non-immune mediated) expression. The presence of a high tumor mutational burden also enriches for response to therapy, and early data indicate that this may provide additive predictive value beyond PD-L1 IHC alone. As candidate biomarkers continue to emerge, the pathologist's assessment of the tumor microenvironment on hematoxylin-eosin stain combined with PD-L1 IHC remains a rapid and robust way to evaluate the tumor-immune dynamic.

KW - PD-(L)1

KW - PD-(L)1 checkpoint blockade

KW - PD-L1 testing

UR - http://www.scopus.com/inward/record.url?scp=85041460620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041460620&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000301

DO - 10.1097/PPO.0000000000000301

M3 - Review article

VL - 24

SP - 41

EP - 46

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 1

ER -